Consider how CABENUVA can fit into your patients' broader health

*Virologic suppression defined as HIV-1 RNA <50 copies/mL.1

†Data from a post-hoc analysis in BEYOND, where adherence was assessed using the previous injection date as the basis for the subsequent injection date and the ±7-day dosing window.1

Move patients forward to CABENUVA

Whether they’re early or established in their treatment journey, take virologically suppressed patients forward to CABENUVA

See how patients like yours could benefit from a long-acting regimen

Experts and colleagues share their experiences moving patients to CABENUVA

Explore your options on how to access CABENUVA

Access & Acquisition

3TC=lamivudine; ABC=abacavir; ART=antiretroviral therapy; DTG=dolutegravir; TAF=tenofovir alafenamide; TDF=tenofovir disoproxil fumarate.

References:

  1. Blick G, Santiago-Colon L, Richardson D, et al. Clinical outcomes at month 24 after initiation of cabotegravir and rilpivirine long acting (CAB+RPV LA) in an observational real-world study (BEYOND). Presented at the 13th IAS Conference on HIV Science; July 13-17, 2025; Kigali, Rwanda, and virtually. EP1078.
  2. Rolle C-P, et al. Early switch to CAB + RPV LA in treatment-naive adults with HIV-1: Month 11 outcomes from VOLITION. Presented at the Conference on Retroviruses and Opportunistic Infections, February 22-25, 2026, Denver, CO. P525.

PMUS-CBRWCNT260007

ART=antiretroviral therapy.

References:

  1. Blick G, Santiago-Colon L, Richardson D, et al. Clinical outcomes at month 24 after initiation of cabotegravir and rilpivirine long acting (CAB+RPV LA) in an observational real-world study (BEYOND). Presented at the 13th IAS Conference on HIV Science, July 13-17, 2025, Kigali, Rwanda, and virtually. EP1078.
  2. Rolle C-P, et al. Early switch to CAB + RPV LA in treatment-naive adults with HIV-1: Month 11 outcomes from VOLITION. Presented at the Conference on Retroviruses and Opportunistic Infections, February 22-25, 2026, Denver, CO. P525.

PMUS-CBRWCNT260007